drugset / Trial / NCT03594175

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175

Phase 3 Terminated 462 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.

Timeline

Start
2020-02-12
Primary completion
2023-06-08
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 2 mg/ml Other
Subject reteplase Protein / enzyme biologic 0.7 mg Other